Trifacet AK/LRI Micrometer Diamond Knife w/Single Footplate
Description:With A Micrometer Handle, Designed To Dial An Exact Extension Of The Diamond Blade. Special Single Footplate Allows Maximum Visibility, With Titanium Handle & Spring. Unique 1mm Snub Nose Blade Tracks Better In Tissue, And Can Also Be Dialed To Full Extension For Making A Paracentesis. Reusable, Autoclaveable, Made In The USA, Handle Guaranteed For Life & Available For A Surgica...Limbal Relaxing Incisional Micrometer Knife
Description:New! Visually superior, micrometer handle, single foot plate, blade extends to 3.0 mm....Newman Astigmatic Micrometer Knife
Description:Astigmatic incisional corneal surgery has long been a very important part of the ophthalmology practice. To ensure optimum results requires both the technical skills and a Surgical Diamond Knife of unparalleled quality. The new "Newman Astigmatic Micrometer Knife" provides such quality....Micromet, Inc. to Present at the 3rd Annual C.E. Unterberg, Towbin Emerging Growth Conference
BETHESDA, Md., July 05, 2007 /PRNewswire-FirstCall/ -- Micromet,Inc. , a biopharmaceutical company focusing on the development ofnovel, proprietary antibody-based products for cancer, inflammatoryand autoimmune diseases, today announced that Dr. Christian Itin,President and Chief Executive Officer of Micromet, Inc., willpresent at the 3rd Annual C.E. Unterberg, Towbin Emerging GrowthConf...Micromet Achieves Milestone in BiTE Research Collaboration with MedImmune
CARLSBAD, Calif., April 23, 2007 /PRNewswire-FirstCall/Micromet, Inc. today announced the achievement of a milestone inits research collaboration with MedImmune, Inc. for the developmentof new BiTE(R) molecules targeting carcinoembryonal antigen (CEA),a validated tumor- associated antigen frequently expressed onvarious human carcinomas. Preclinical data recently presented atthe 2007 Annu...MedImmune and Micromet Publish Data on Novel Anti-Cancer BiTE Molecule
- New Compound Targeting Receptor Tyrosine Kinase EphA2 Shows TumorDestruction at Low Dose Levels in Preclinical Models - GAITHERSBURG, Md. and CARLSBAD, Calif., April 19, 2007/PRNewswire-FirstCall/ -- MedImmune, Inc. and Micromet, Inc. todayannounced that published proof-of-concept data with a new BiTE(R)molecule (bscEphA2xCD3) show that the compound killed tumor cellsat dose levels cons...Micromet and MedImmune Present Data From Preclinical Study of New BiTE Molecule Targeting CEA
GAITHERSBURG, Md. and CARLSBAD, Calif., April 18, 2007/PRNewswire-FirstCall/ -- Micromet, Inc. and MedImmune, Inc. todayannounced data from a preclinical study in which BiTE(R) moleculestargeting carcinoembryonal antigen (CEA) were shown to preventsubcutaneous tumor growth and formation of lung metastases. Anestablished marker for tumor progression, CEA is frequentlyexpressed on breast,...